<DOC>
	<DOCNO>NCT00169247</DOCNO>
	<brief_summary>Larynx preservation remain challenging approach patient larynx/pharynx cancer . A first attempt consist induction chemotherapy follow good responder irradiation . This approach allow preserve 60 % larynx without significant difference survival . The second attempt consist concurrent chemo-irradiation . This approach provide high larynx preservation rate survival remain unchanged mucosal toxicity also high . A third approach currently evaluation : induction chemotherapy follow concurrent chemo-irradiation good responder .</brief_summary>
	<brief_title>Radiotherapy With Cisplatin Versus Radiotherapy With Cetuximab After Induction Chemotherapy Larynx Preservation</brief_title>
	<detailed_description>At ASCO 2004 3 major presentation issue increase survival : - update MACH-NC meta-analysis show actually concurrent chemo-irradiation trial find significantly improve survival ( particular addition cisplatinum alone radiotherapy ) - addition docetaxel cisplatinum-5FU regimen ( TPF ) compare cisplatinum -- 5FU ( PF ) - addition cetuximab irradiation On basis decide carry-out randomized phase II previously untreated patient require total laryngectomy : All patient complete work-up include CTscan receive 3 cycle TPF ( T : 75 mg/m² , P : 75 mg/m² 5FU 750 mg/m² ) . Patients response 50 % ( endoscopy CTscan ) randomize receive either irradiation ( 70 Gy ) cisplatinum ( 100 mg/m² D1 , D22 D43 ) irradiation ( 70 Gy ) cetuximab ( load dose 400 mg follow weekly 250 mg total 8 cycle . Patients less 50 % decease tumour volume TPF , patient residual recurrent disease either RT-CDDP RT-cetuximab get salvage total laryngectomy .</detailed_description>
	<mesh_term>Laryngeal Diseases</mesh_term>
	<mesh_term>Laryngeal Neoplasms</mesh_term>
	<mesh_term>Hypopharyngeal Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Larynx hypopharynx squamous cell carcinoma proven histology , locally advanced , eligible surgery total subtotal ( pharyngo ) laryngectomy Performance status 01 Neutrophils &gt; =1.5 x 109/l , Platelets count &gt; =100 x 109/l , haemoglobin &gt; =10 g/dl Total bilirubin &lt; = 1.5 x upper reference range ASAT ALAT &lt; = 2.5 x upper reference range , Alkaline Phosphatases &lt; = 5 x upper reference range Serum creatinine &lt; = 120 µmol/l Weight loss &lt; 10 % within last 3 month Written inform consent Infiltrative transglottic tumor clinical cartilage invasion Distant metastasis Previous chemotherapy radiotherapy Contraindication chemotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>larynx cancer</keyword>
	<keyword>hypopharynx cancer</keyword>
	<keyword>larynx preservation</keyword>
	<keyword>concomitant radiochemotherapy</keyword>
	<keyword>cisplatin</keyword>
	<keyword>cetuximab</keyword>
	<keyword>randomize trial</keyword>
</DOC>